spacer
home > pmps > winter 2002 > taking control of your terminology
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Taking Control of your Terminology

For most people, terminology does not tend to be an all-consuming obsession. They're just words, right? In the grand scheme of things, terminology hardly features up there with AIDS in Africa and the Middle East crisis as discussion points. Let's face it, if the guy next to you at the bar starts talking about terminology, you'll almost certainly look at your watch and say, "Gosh, is that time? I really must dash!"

When it comes to terminology, familiarity breeds contempt. Authors writing corporate documentation, be it marketing brochures, technical manuals, catalogues or web content, should know which terms to use. If they don't, they'd better stop authoring and do something else. So why worry about it? We need to look at two important issues - quality management and translation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Bob Clark, Solutions Consultant with the Logos Group of Companies
Bob Clark is a Solutions Consultant with the Logos Group of Companies in Modena, Italy. Raised in California and educated in the UK, he graduated from the University of Leeds with a Joint Honours Degree in Arabic and Russian and now holds the post of Senior Lecturer in Translation Technology at the same university.

He is Joint-Editor of Language International, a publication dedicated to the dissemination of developments affecting all aspects of the multilingual documentation production process, including authoring, translation and publication. Bob also holds a directorship in the International Trade Association of Greater Chicago.

spacer
Bob Clark
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement